PSSI-51

• Description :

  PSSI-51 is an orally active, peripherally selective inhibitor of succinyl-CoA:3-ketoacid-CoA transferase (SCOT) . PSSI-51 inhibits SCOT activity in peripheral tissues (such as muscle and kidney) but does not affect SCOT activity in brain tissue. PSSI-51 reduces ketone body oxidation by inhibiting SCOT, thereby improving obesity-related hyperglycemia. PSSI-51 can be used in the study of type 2 diabetes (T2D) and has the potential to improve obesity-related metabolic disorders[1].

• UNSPSC :

  12352005

• Target :

  Others

• Related Pathways :

  Others

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Purity :

  99.75

• Smiles :

  O=C(N1CCCN2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)C5=CC=CC=C5C1=O.Cl.Cl

• Molecular Formula :

  C28H29Cl2F2N3O2

• Molecular Weight :

  548.45

• References & Citations :

  [1]Tabatabaei Dakhili, et al. Development of a succinyl CoA:3-ketoacid CoA transferase inhibitor selective for peripheral tissues that improves glycemia in obesity. iScience, Volume 28, Issue 5, 1123361.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported